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Introduction
The invention of the loop-mediated iso-
thermal amplification (LAMP) method a
decade ago has given new impetus towards
development of point of care diagnostic
tests based on amplification of pathogen
DNA, a technology that has been the
precinct of well-developed laboratories.
The LAMP technology amplifies DNA
with high sensitivity relying on an enzyme
with strand displacement activity under
isothermal conditions. Additionally, the
technology uses four to six specially de-
signed primers recognising six to eight
regions of the target DNA sequence, hence
a high specificity. The auto-cycling reac-
tions lead to accumulation of a large
amount of the target DNA and other
reaction by-products, such as magnesium
pyrophosphate, that allow rapid detection
using varied formats [1,2]. Over the last
10 years, LAMP has been used widely in
the laboratory setting to detect pathogens
of medical and veterinary importance,
plant parasitic diseases, genetically modi-
fied products, and tumour and embryo sex
identification, among other uses [3].
However, its application under field con-
ditions has been limited, partly due to the
infancy of the technologies associated with
LAMP, such as field-based template prep-
aration methods and product detection
formats. In this Viewpoint, the author
highlights the essential technologies that
require development before the LAMP
platform can be progressed into a realistic
point of care format for resource-poor
endemic areas.
ASSURED Tests
Lack of effective point of care diagnostic
tests applicable in resource-poor endemic
areas is a critical barrier to effective treat-
ment and control of infectious diseases.
Indeed, this paucity is acutely demonstrat-
ed in neglected tropical diseases (NTDs),
where access to reliable diagnostic testing
is severely limited and misdiagnosis com-
monly occurs. Although the reasons for
the failure to prevent and control NTDs in
the developing world are complex, a major
barrier to effective health care is the lack
of access to reliable diagnostic laboratory
services [4]. The World Health Organiza-
tion (WHO) recommends that an ideal
diagnostic test suitable for developing
countries should be Affordable, Sensitive,
Specific, User-friendly (simple to perform
in a few steps with minimal training),
Robust and rapid (results available in
30 min), Equipment free, and Deliverable
to the end user (ASSURED) [5]. So far,
only a few rapid diagnostic test (RDT)
formats fit this model, albeit with limited
sensitivity and specificity [6]. Nucleic acid
(DNA) amplification tests targeting patho-
gen markers have high sensitivity and
specificity but generally fail to meet the
ASSURED guidelines in terms of afford-
ability, rapidity, and being equipment free
[7]. However, with the recent invention
and advancement of isothermal technolo-
gies [8], development of ASSURED tests
based on DNA amplification seems realis-
tic. One such potential method is the
LAMP technology, which has salient ad-
vantages over most DNA-based amplifica-
tion tests (Box 1). These characteristics
make LAMP strategy a potential AS-
SURED platform. However, for LAMP
technology to demonstrate the perfor-
mance goals implied in the ASSURED
guidelines, four technologies that are ap-
plicable with the LAMP test need to be
developed. These include template prepa-
ration protocols, a lysophilised kit, a re-
liable power source, and product detection
technologies.
Template Preparation Protocol
The LAMP method hasthe advantage of
amplifying the target DNA from partially
processed and/or non-processed samples
[9]. This inherent advantage of LAMP
shortens the reaction time and eliminates
the need for DNA extraction, a step that is
prone to contamination and may result in
significant loss of DNA. The preparation of
template DNA is the least developed
method associated with LAMP technology.
For example, the ideal specimens (biolog-
ical fluids, tissue, swabs, scraping etc.)
(Figure 1A) for LAMP reactions are yet to
be determined. The direct use of native
cerebrospinal fluid, serum, heat-treated
blood [10], and addition of detergent [11]
have yielded viable DNA templates; how-
ever, precise preparation protocols need to
be defined and optimised. Nevertheless,
these results offer exciting possibilities that
definition of a simple field-based template
preparation protocol is possible. To im-
prove the performance of LAMP tests,
methodologies for specimen collection and
processing need to be simple, optimised,
and ensure high target yields. In addition,
selected buffers should not only stabilise the
DNA (reduce degradation in case of
storage), but should also enhance amplifi-
cation whenever possible. An ideal tem-
plate protocol will thus depend on the
sample being tested. For example, whole
blood, stool, and tissue specimens may
include direct boiling followed by a single
buffer-purification step to separate the
template from the debris or application of
a sample preparation kit that readily
removes unwanted biological products
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tion of the template (Figure 1B). Such
developments should be approached with
the primary aim of reducing cost and
potential LAMP inhibitors.
Lyophilisation of LAMP Recipe
A standard LAMP reaction consists of a
large amount of reaction components
(reagents), namely the enzyme and its
buffer, deoxynucleotide triphosphates, be-
taine, three sets of primers of varied
concentrations, and the detection dye.
The researcher/technician is not only
faced with the task of acquiring different
reagents from varied sources, but the
requirement for the cold chain is a major
cost during transportation and storage.
For example, transporting LAMP reagents
from Australia/Europe to Africa requires
dry ice as well as expensive flight charges.
Furthermore, when the shipment is being
sent to multiple recipients, the risk of
exposure increases dramatically and is
hence a source of varied results. To reduce
the test manipulation, Eiken Chemical
Co., Japan, developed general LAMP
DNA and RNA kits (http://www.eiken.
co.jp/en/product/); however, the cold
chain is still a requirement. Previous
studies indicated that LAMP reagents
were stable at temperatures of up to
37uC, raising the possibility of lyophilisa-
tion [12], an objective that was recently
achieved when Eiken Chemical Co.
launched a lyophilised kit for sleeping
sickness (http://www.eiken.co.jp/en/
news/pdf/20110916-1.pdf). Another ex-
perimental lyophilised LAMP kit for
animal diseases is under evaluation by
the International Atomic Energy Agency
(IAEA) and the results are promising
(Herman Unger, personal communica-
tion). Since different pathogen biomarkers
operate under different LAMP conditions
[13], development of a general LAMP kit
that requires only addition of specific
pathogen primers is not feasible. As such,
an ideal LAMP kit will be disease specific
and possibly consist of a lyophilised master
mix (including the primers) and only
require re-constitution and sample addi-
tion (Figure 1C). Moreover, the kit should
be affordable and stable under hot and
humid tropical conditions.
Reliable Power Source
One of the primary barriers to the
practicality of LAMP under field condi-
tions is the requirement of electricity to
run the test and refrigerate the reagents.
However, LAMP reactions are rapid and
proceed at a lower temperature (,60uC)
compared to PCR, meaning that less time
and heat is required to complete incuba-
tion. This is attributable to the use of DNA
polymerase with a strand displacement
activity. The prevailing conditions in most
disease-endemic regions dictate that the
source of power for ASSURED tests needs
to be reliable and possibly portable within
rugged environmental conditions; there-
fore, electricity-free technologies such as a
water incubator heated with wood or
charcoal, re-chargeable batteries (includ-
ing solar based), engineered mechanical
devices, and exothermal chemical units
are most appropriate. Indeed, such simple
to operate prototype devices have been
developed based on calcium oxide or
quicklime [14] and a battery-operated
and portable fluorescence reader (ESE-
Quant Tube Scanner, Qiagen ESE
Gmbh, Stockach, Germany) (Figure 1D).
Among these, the ESEQuant Tube Scan-
ner is most advanced and has several
advantages in that it offers (i) a single-step
amplification and product detection, (ii)
results can be monitored in real time using
a program installed in a laptop (Figure 1E)
and/or through an LCD window, (iii) a re-
chargeable battery, and (iv) is simple to
operate, small 74 (h)6178 (w)6188 mm,
and light weight (1 kg). The downside of
the unit is that it runs only eight samples
and uses non-specific dye for detection of
double-stranded DNA (dsDNA). Never-
theless, the ESEQuant Tube Scanner pro-
vides the first major advancement towards
‘‘electricity free’’ technology for LAMP
technology. The next major step is rigor-
ous evaluation of the ESEQuant Tube
Scanner and possibly its modification to
accommodate more samples. Other po-
tential sources of heat include sodium
acetate (heat pads), which can be packaged
into customised and insulated units. Such
a device will require clicking a metal disc
to initiate nucleation and crystallization to
reach temperatures of $54uC for over an
hour and sufficient for LAMP reactions
using Bsm DNA polymerase (unpublished
data). Sodium acetate is non-toxic and the
heat pads can easily be recharged by
boiling in water and reused many times.
Detection of LAMP Product
Significant progress has been made with
modification of the LAMP method, but
the product detection technologies have
not seen similar advancement. The LAMP
reaction produces large amounts of mag-
nesium pyrophosphate (a white precipi-
tate) and dsDNA, which allow visual
inspection of results using a turbidimeter
and real-time PCR machine, respectively,
avoiding post DNA amplification manip-
ulation (Figure 1E and 1F). To achieve a
white precipitate, extra Mg
++ is required,
which may compromise test specificity
[10], while fluorescence dyes have a major
limitation in that they can bind non-
specifically to any dsDNA, such as prim-
er-dimers, leading to erroneous result in-
terpretation. Other reported non-specific
dyes include calcein and and hydroxy
naphthol blue, which are incubated with
the reaction, and SYBR Green I, which is
added after the reaction, a step that may
lead to subsequent contamination once the
tubes are opened. A higher test specificity
can be achieved by targeting an internal
sequence of the amplicon through incor-
porating fluorescent molecular beacon
probe, thus minimising non-specific signal
[15], or by using a lateral flow dipstick
(LFD) format (Figure 1G) [16], though at a
slightly higher cost. In general, the use of
dyes is most preferred because they are
cheap and most allow definite visual in-
spection of results based on colour change
[17]. However, the need for treatment
and/or a decision on case management
dictates unequivocal result interpretation.
Thus, any LAMP detection format should
not compromise specificity for simplicity.
An ideal LAMP detection format would
Box 1. The Advantages of LAMP Technology
1. Less expensive (less instrumentation required to achieve amplification)
2. Rapid (results obtained within 1 hour)
3. Sensitivity (equal to or higher to that of classical PCR targeting the same gene)
4. Robust (can amplify target DNA from partially processed or unprocessed
specimen)
5. Specificity (high specificity since four to six primes are used targeting six to
eight DNA target regions)
6. Product detection (large amount of dsDNA formed and magnesium pyrophos-
phate allow visual detection formats)
7. Amplification at isothermal conditions (low heat required, hence water bath and
exothermal chemical units are sufficient)
www.plosntds.org 2 June 2012 | Volume 6 | Issue 6 | e1572Figure 1. A proposed three-step LAMP method for diagnosis of neglected tropical diseases. Step 1 includes processing of varied
specimen (A) through boiling or use of kits to yield a stable and concentrated DNA template (B). In step 2, the lyophilised master mix (C) is
reconstituted by the addition of water and the ideal amount of DNA template. In step 3, the amplification and the detection format are combined
into a single step to avoid opening the tube (D), hence the results can be acquired in real time (E) through incubation of the reaction with a reporting
dye (F) and through the use of a novel LAMP LFD format.
doi:10.1371/journal.pntd.0001572.g001
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detection unit to limit contamination and
use of a dye of acceptable specificity and/
or a novel LFD format. For example, it is
worth noting that the human African
trypanosomiasis case definition requires
demonstration of trypanosomes in the
body fluid, and that the LAMP test may
not be relied upon to make a treatment
decision. Nevertheless, the expected high
specificity of LAMP may reduce costs as-
sociated with serological false positives that
card agglutination test for trypanosomiasis
(CATT) registers, of which only few end
up being genuine HAT cases.
Future Direction
The way forward for LAMP as a point of
care diagnostic platform requires a con-
tinuing quest to advance the technology
into ASSURED format. A field-based
LAMP test may consist of three to four
diagnostics steps or fewer, depending on
the type of specimen (Figure 1). Achieving
such formats require concerted innovative
research efforts, an objective that is strained
by lack of funding. Noticeable achievement
has been made through collaboration be-
tween academia and philanthropic organi-
sations. In this context, the Foundation for
Innovative New Diagnostic (FIND), Gene-
va, academia, and Eiken Chemical Co.
have progressed the repetitive insertion
mobile element (RIME) LAMP for sub-
genus Trypanozoon (sleeping sickness) into a
field-applicable format. Furthermore, the
Stop Buruli initiative and the University of
Queensland are working towards a field-
based Buruliulcer disease test format.Since
considerable progress has been gained in
advancement of the LAMP platform, more
efforts need to be directed towards devel-
opment of the associated technologies. This
should be followed by rigorous evaluation
of test performance to determine feasibility
and acceptability under field conditions. It
is the completion of these indispensible
technologies that will lead to realisation of a
LAMP-based point of care test. Since
LAMP technology shows much potential
as a diagnostic tool for NTDs, sustainable
programmes for quality assurance need to
be established alongside various technolog-
ical formats. Further, to ensure a continued
production of kits beyond project life, in-
corporation of a commercialisation plan is
advisable.
Conclusion
Diagnostic testing, and in particular early
detection, is critical for most NTDs, as most
infected individuals are often asymptomatic
but nonetheless sick and infectious. As such,
sensitive diagnostic tests are required to
guide treatment, minimise drug exposure to
non-infected individuals, and interrupt dis-
ease transmission. The rapid pace inLAMP
technology development and the current
support from philanthropic groups and
other funding agencies makes it more likely
thatin thenext5 yearswemayhave specific
LAMP tests applicable at the point of care.
It is suggested here that the technologies
associated with LAMP be considered and
developed as part of a LAMP platform,
rather than developing them as separate
entities. This will mean apportioning the
available funding in developing these for-
mats. Considering LAMP’s simplicity in
operation and high sensitivity, there is po-
tential use in clinical diagnosis and surveil-
lanceofinfectiousdiseases.Toachievethese
levels in resource-poor endemic areas, spe-
cimen processing methods, production of
lyophilised kits, and a closed amplification
and detection system need to be developed.
This will facilitate the provision of a same-
day testing strategy in even the most remote
rural health facilities.
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